Chronic spontaneous urticaria might affect elderly patients, causing a serious impairment of their quality of life. The therapeutic management of the elderly patient is challenging; in fact, the first-line recommended therapy for symptom control are antihistamines, that may have interactions or increased risk of side effects in patients with comorbidities and poly-pharmacological regimen. Omalizumab is the first biological drug approved for chronic spontaneous urticaria resistant to antihistamines. Real-life data focusing on patients >65-year-old treated with omalizumab are rare. In our retrospective study, we evaluated the efficacy and safety of this biologic therapy in patients over 65-year-old. We performed Urticaria Activity Score-7 (UAS-7) in order to evaluate the efficacy of omalizumab and the time of remission. We collected any adverse event related to the treatment. Moreover, we investigated the presence of comorbidities and their impact on the efficacy of omalizumab. Sixty-threepatients, with a mean age of 72.3 ± 5.6 years, range: 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an “early complete response” profile, which means the achievement of a UAS7 score of “0” within the first 7 days of therapy. The most frequent comorbidity was hypertension, which affected 26 of 63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities. Omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities.

It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients / E. Martina, G. Damiani, T. Grieco, C. Foti, P.D.M. Pigatto, A. Offidani. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 34:2(2021 Mar), pp. e14841.1-e14841.3. [10.1111/dth.14841]

It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients

G. Damiani
Co-primo
;
P.D.M. Pigatto;
2021

Abstract

Chronic spontaneous urticaria might affect elderly patients, causing a serious impairment of their quality of life. The therapeutic management of the elderly patient is challenging; in fact, the first-line recommended therapy for symptom control are antihistamines, that may have interactions or increased risk of side effects in patients with comorbidities and poly-pharmacological regimen. Omalizumab is the first biological drug approved for chronic spontaneous urticaria resistant to antihistamines. Real-life data focusing on patients >65-year-old treated with omalizumab are rare. In our retrospective study, we evaluated the efficacy and safety of this biologic therapy in patients over 65-year-old. We performed Urticaria Activity Score-7 (UAS-7) in order to evaluate the efficacy of omalizumab and the time of remission. We collected any adverse event related to the treatment. Moreover, we investigated the presence of comorbidities and their impact on the efficacy of omalizumab. Sixty-threepatients, with a mean age of 72.3 ± 5.6 years, range: 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an “early complete response” profile, which means the achievement of a UAS7 score of “0” within the first 7 days of therapy. The most frequent comorbidity was hypertension, which affected 26 of 63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities. Omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities.
chronic spontaneous urticaria; drugs aging; elderly; metabolic syndrome; omalizumab;
Settore MEDS-10/C - Malattie cutanee e veneree
mar-2021
1-feb-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dermatologic Therapy - 2021 - Martina - It is never too late to treat chronic spontaneous urticaria with omalizumab .pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 419.49 kB
Formato Adobe PDF
419.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1115661
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact